Avalo Therapeutics (AVTX) EBT (2014 - 2026)

Avalo Therapeutics (AVTX) has 13 years of EBT data on file, last reported at -$19.6 million in Q1 2026.

• Quarterly EBT fell 49.29% year-over-year to -$19.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$84.6 million (down 215.65% YoY) and the FY2025 annual result came in at -$78.1 million, down 123.03% from the prior year.
• EBT eased to -$19.6 million in Q1 2026, from -$13.6 million in the prior quarter.
• In the past five years, EBT ranged from a high of $98.5 million in Q2 2024 to a low of -$121.3 million in Q1 2024.
• A 5-year average of -$12.1 million and a median of -$13.0 million in 2022 frame the typical range for EBT.
• The widest YoY moves for EBT: up 1302.91% in 2024, down 1119.29% in 2024.
• Tracing AVTX's EBT over 5 years: stood at -$9.8 million in 2022, then advanced by 16.6% to -$8.2 million in 2023, then slumped by 330.78% to -$35.2 million in 2024, then surged by 61.42% to -$13.6 million in 2025, then slumped by 44.36% to -$19.6 million in 2026.
• The last three EBT figures came in at -$19.6 million (Q1 2026), -$13.6 million (Q4 2025), and -$30.6 million (Q3 2025), per Business Quant data.